Has Jorge Amaya received payments from drug or device companies?

Yes. Drug and device makers reported $290 in general payments to Jorge Amaya across 2 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jorge Amaya did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jorge Amaya come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jorge Amaya

General Practice · Miami, FLNPI 1811093735

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Amgen accounts for 94.9% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for general practice clinicians in FL, where the typical reported total is $253.

$290in general payments, 2019–2025

Across 2 payments — averaging $144.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$275
AstraZeneca$15

$14,219,438in research payments, 2019–2025

Across 152 payments — averaging $93,549 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Amgen$12.3M
Genentech, Inc.$1.2M
Teva Pharmaceuticals USA, Inc.$203K
Paratek Pharmaceuticals, Inc.$170K
AbbVie$144K
Astrazeneca UK Limited$101K
plus $163K from 8 others

What the payments were for

Food & beverage$290100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	1	$275
AstraZeneca	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

KRYSTEXXA$275

How this compares

$290 in reported general payments places this provider in the 50th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	202	$2,797
Temazepam	18	$478
Olmesartan Medoxomil	13	$77
Estradiol	12	$65
Metoprolol Tartrate	15	$65
Alprazolam	20	$54

Paid to pharmacies, not to this prescriber.

Other general practice in Miami

Idalia AcostaMiami$99K
Eddie GomezMiami$59K
Aladino ValienteMiami$24K
Viviana WaichMiami$20K
Libia RiosMiami$15K
Jose CardonaMiami$15K
Rosa HuguetMiami$15K
Robert VogelPalm Beach Gardens$1M
Bruce OuelletteWest Palm Beach$724K
Caley CasteleinMiami Beach$586K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →